MMW - Fortschritte der Medizin

, Volume 154, Issue 25–26, pp 46–53 | Cite as

So treffen Sie die richtige Wahl

Orale Antidiabetika
FORTBILDUNG ÜBERSICHT
  • 17 Downloads

Die derzeit verfügbaren oralen Antidiabetika greifen an unterschiedlichen Ansatzpunkten in der Pathogenese des Typ-2-Diabetes an. Welches sind die Vor- und Nachteile der einzelnen Substanzen? Welche Kombinationsmöglichkeiten bestehen?

Keywords - Oral antidiabetics: how you take the right choice

Antihyperglycemic therapy indication contraindications adverse effects combination therapy 

Literatur

  1. 1.
    A DeFronzo RA. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 2009; 58: 773–95.CrossRefGoogle Scholar
  2. 2.
    S. Matthaei, R. Bierwirth, A. Fritsche, B. Gallwitz, H.-U. Häring, H.-G. Joost et al. Medikamentöse antihyperglykämische Therapie des Diabetes mellitus Typ 2 Update der Evidenzbasierten Leitlinie der Deutschen Diabetes-Gesellschaft. Diabetologie 2009; 4: 32–64CrossRefGoogle Scholar
  3. 3.
    Piccinni C, Motola D, Marchesini G, Poluzzi E. Assessing the Association of Pioglitazone Use and Bladder Cancer Through Drug Adverse Event Reporting. Diabetes Care 2011 34:1369–1371PubMedCrossRefGoogle Scholar
  4. 4.
    Tzoulaki I, Molokhia M, Curcin V, Little MP, Millett CJ, Ng A, Hughes RI, Khunti K, Wilkins MR, Majeed A, Elliott P. Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database. BMJ. 2009; 339:b4731.PubMedCrossRefGoogle Scholar
  5. 5.
    S. Matthaei, R. Bierwirth, A. Fritsche, B. Gallwitz, H.-U. Häring, H.-G. Joost et al. Praxisempfehlungen der Deutschen Diabetes-Gesellschaft. Diabetologie und Stoffwechsel 2011; S2:105–210.Google Scholar
  6. 6.
    Solomon TP, Haus JM, Kelly KR, Cook MD, Filion J, Rocco M, Kashyap SR, Watanabe RM, Barkoukis H, Kirwan JP. A low-glycemic index diet combined with exercise reduces insulin resistance, postprandial hyperinsulinemia, and glucose-dependent insulinotropic polypeptide responses in obese, prediabetic humans. Am J Clin Nutr. 2010;92(6):1359–68.PubMedCrossRefGoogle Scholar
  7. 7.
    Bailey CJ, Turner RC: Metformin. N Engl J Med. 1996; 334:574–579.PubMedCrossRefGoogle Scholar
  8. 8.
    Gallagher EJ, LeRoith D. Diabetes, cancer, and metformin: connections of metabolism and cell proliferation. Ann N Y Acad Sci. 2011; 1243:54–68.PubMedCrossRefGoogle Scholar
  9. 9.
    Chan NN, Brain HP, Feher MD: Metformin-associated lactic acidosis: a rare or very rare clinical entity? Diabetes Care. 1998; 21:1659–1663.CrossRefGoogle Scholar
  10. 10.
    Garber A, Duncan T, Goodman A, et al. Efficacy of metformin in type-II diabetes: results of a double-blind, placebo-controlled, dose-response trial. Am J Med. 1997; 102:491–497.CrossRefGoogle Scholar
  11. 11.
    Yki-Järvinen H, Rysy L, Nikkiä K, et al. Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus. Ann Intern Med. 1999; 130:389–396.PubMedGoogle Scholar
  12. 12.
    Holman RR, Cull CA, Turner RC. A randomized double-blind trial of acarbose in type 2 diabetes shows improved glycemic control over 3 years (U.K. Prospective Diabetes Study 44). Diabetes Care. 1999; 22:960–964.PubMedCrossRefGoogle Scholar
  13. 13.
    Chiasson JL, Josse RG, Gomis R, et al. STOP-NIDDM Trial Research Group. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA. 2003; 290:486–94.PubMedCrossRefGoogle Scholar
  14. 14.
    Nathan DM. Finding new treatments for diabetes — how many, how fast... how good? N Engl J Med. 2007; 356:437–40.PubMedCrossRefGoogle Scholar
  15. 15.
    UK Prospective Diabetes Study (UKPDS 33) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet. 1998; 352:854–65.CrossRefGoogle Scholar
  16. 16.
    Holstein A. Lower incidence of severe hypoglycaemia in patients with type 2 diabetes treated with glimepiride versus glibenclamide. Diabetes Metab Res Rev. 2001; 17:467–473.PubMedCrossRefGoogle Scholar
  17. 17.
    Klepzig H, Kober G, Matter C, et al. Sulfonylureas and ischaemic preconditioning: a double-blind, placebo-controlled evaluation of glimepiride and glibenclamide. Eur Heart J. 1999; 20:439–446.PubMedCrossRefGoogle Scholar
  18. 18.
    Rosenstock J, Hassman DR, Madder RD, et al. Repaglinide Versus Nateglinide Comparison Study Group: Repaglinide versus nateglinide monotherapy: a randomized, multicenter study. Diabetes Care. 2004; 27:1265–70.PubMedCrossRefGoogle Scholar
  19. 19.
    NAVIGATOR Study Group, Holman RR, Haffner SM, McMurray JJ, et al. Effect of nateglinide on the incidence of diabetes and cardiovascular events. N Engl J Med. 2010; 362(16):1463–76.PubMedCrossRefGoogle Scholar
  20. 20.
    Neumiller JJ. Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors. J Am Pharm Assoc.2009; 49 Suppl 1:S16–29.CrossRefGoogle Scholar
  21. 21.
    Derosa G, Maffioli P. Dipeptidyl Peptidase-4 Inhibitors: 3 Years of Experience. Diabetes Technol Ther. 2012 Feb 10. [Epub ahead of print]Google Scholar

Copyright information

© Urban & Vogel 2012

Authors and Affiliations

  1. 1.Klinik für Endokrinologie, Diabetologie und Angiologie, Städt. Klinikum München GmbH, Klinikum BogenhausenMünchenDeutschland

Personalised recommendations